Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020
Avidity Biosciences (Nasdaq: RNA) will present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on November 12, 2020, at 8:45 am PST. Sarah Boyce, the President and CEO, will lead the presentation in a virtual format. A live webcast will be available on the company's website, with an archived replay accessible for one year. Avidity is focused on developing innovative oligonucleotide-based therapies, including their lead candidate AOC 1001 for treating myotonic dystrophy type 1, as well as therapies for muscle atrophy and other serious diseases.
- None.
- None.
LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST. The conference is being held in a virtual format.
A live webcast of the virtual fireside chat will be available on the Company's website at www.aviditybiosciences.com in the Investor Resources section. A replay of the fireside presentation will be archived on the site for one year.
About Avidity Biosciences
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead
product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.
Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn.
Contacts:
Company:
Mike MacLean
(858) 401-7900
mikemaclean@aviditybio.com
Media and Investors:
Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/avidity-biosciences-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-conference-2020-301167367.html
SOURCE Avidity Biosciences, Inc.
FAQ
When will Avidity Biosciences present at the Credit Suisse Healthcare Conference?
Who is presenting for Avidity Biosciences at the conference?
Where can I watch Avidity Biosciences' presentation?
What is Avidity Biosciences' lead product candidate?
What innovative therapies does Avidity Biosciences develop?
